1 st European Myeloma Network Meeting

Transcription

1 PRELIMINARY PROGRAM 1 st European

2 TIMETABLE Thursday, April 19, 2018 Friday, April 20, 2018 Saturday, April 21, MEET THE EXPERTS MEET THE EXPERTS OPENING CEREMONY OPENING LECTURE TREATMENT STRATEGY IN MULTIPLE MYELOMA PATIENTS AT DIAGNOSIS RECOMMENDATIONS AND CHALLENGES: HOW TO MAKE SENSE OF THE MANY TREATMENT OPTIONS AVAILABLE TREATMENT STRATEGY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: NOVEL THERAPIES, WHEN AND IN WHICH PATIENTS? BEST ABSTRACTS II - ORAL PRESENTATIONS MGUS AND SMM: RECOMMENDATIONS AND CHALLENGES LUNCH and POSTER VIEWING SPONSORED SATELLITE SYMPOSIUM NO RECOMMENDATIONS AND CHALLENGES: HOW TO MAKE SENSE OF THE MANY TREATMENT OPTIONS AVAILABLE AT RELAPSE SPONSORED SATELLITE SYMPOSIUM NO PATIENT PERSPECTIVE: PATIENT ASSOCIATION TALKS SIDE EFFECTS MANAGEMENT MULTIPLE MYELOMA BIOLOGY AND GENOMICS LUNCH and POSTER VIEWING CONCLUSIONS AND FINAL GREETINGS SPONSORED SATELLITE SYMPOSIUM NO SPONSORED SATELLITE SYMPOSIUM NO SPECIAL CONDITIONS - WALDENSTRÖM MACROGLOBULINEMIA MINIMAL RESIDUAL DISEASE IN MULTIPLE MYELOMA AGGRESSIVE DISEASE - EXTRAMEDULLARY DISEASE/PLASMA CELL LEUKEMIA SPECIAL CONDITIONS - AMYLOID LIGHT-CHAIN AMYLOIDOSIS WELCOME COCKTAIL BEST ABSTRACTS I - ORAL PRESENTATIONS

3 THURSDAY, APRIL 19, OPENING CEREMONY OPENING LECTURE Myeloma from past to present - R.A. Kyle MGUS AND SMM: RECOMMENDATIONS AND CHALLENGES Chairmen: R.A. Kyle, M.V. Mateos MGUS and SMM - S. Kristinsson M protein related disease - J. Bladé SMM? - M.V. Mateos LUNCH and POSTER VIEWING SPONSORED SATELLITE SYMPOSIUM NO MULTIPLE MYELOMA BIOLOGY AND GENOMICS Chairmen: N.C. Munshi, P. Sonneveld Biology of Multiple Myeloma - M. Raab DEBATE: CAN GENETIC ABNORMALITIES BE TARGETED? Applicable approach? YES - M. Kaiser Applicable approach? NO - P. Sonneveld SPONSORED SATELLITE SYMPOSIUM NO MINIMAL RESIDUAL DISEASE IN MULTIPLE MYELOMA Chairmen: B.G.M. Durie, J. Hillengass MRD techniques - H. Avet-Loiseau Imaging techniques - E. Zamagni RECOMMENDATIONS AND CHALLENGES: How to use MRD in clincal practice - R.G. Owen What kind of trials do we need in the future to address open issues with MRD? - M. Attal AGGRESSIVE DISEASE - EXTRAMEDULLARY DISEASE / PLASMA CELL LEUKEMIA Chairmen: P. Musto, N. van de Donk Biology of aggressive disease - N.C. Munshi Extramedullary disease - L. Rosiñol Plasma cell leukemia - P. Musto WELCOME COCKTAIL

4 FRIDAY, APRIL 20, MEET THE EXPERTS 6 Simultaneous Sessions MGUS and SMM - N. Giuliani, M.V. Mateos MRD in clinical practice - H. Avet-Loiseau, D. Hofste op Bruinink Transplant strategies - G. Jackson, C. Straka Risk adapted therapy in NDMM young - V. Montefusco, P. Sonneveld How to incorporate new agents - C. Driessen, I.S. Nijhof Data manager: how to deal with data management issues - S. Lonegran, R. Troia TREATMENT STRATEGY IN MULTIPLE MYELOMA PATIENTS AT DIAGNOSIS Chairmen: J.F. San Miguel, C. Straka Treatment Strategy: Optimal induction and autologous stem cell transplantation - M. Cavo Transplant strategies: elderly and allo - M. Mohty Post transplantation strategies - P.L. McCarthy Geriatric assessment in the elderly - A. Larocca Treatment strategy in the elderly - S. Zweegman RECOMMENDATIONS AND CHALLENGES: HOW TO MAKE SENSE OF THE MANY TREATMENT OPTIONS AVAILABLE AT DIAGNOSIS Chairmen: M. Attal, P.L. McCharty DEBATE: RISK ADAPTED THERAPY Are we ready? YES - M.A. Dimopoulos Are we ready? NO - J.F. San Miguel Cost/efficacy considerations - M. Engelhardt NDMM? - T. Facon SPONSORED SATELLITE SYMPOSIUM NO PATIENT PERSPECTIVE: PATIENT ASSOCIATION TALKS Chairmen: B.G.M. Durie, H. Goldschmidt LUNCH and POSTER VIEWING SPONSORED SATELLITE SYMPOSIUM NO SPECIAL CONDITIONS - WALDENSTRÖM MACROGLOBULINEMIA Chairmen: X. Leleu, S.P. Treon Diagnostic and prognostic challenges in WM - S.P. Treon Novel targeted treatment options for WM: new challenges - E. Kastritis Management of IgM related disorders - M.J. Kersten SPECIAL CONDITIONS - AMYLOID LIGHT-CHAIN AMYLOIDOSIS Chairmen: J. Bladé, G. Merlini Mechanisms of disease and biomarkers - G. Merlini Diagnosis, risk stratification and response assessment - M. Minnema Established and novel therapies - G. Palladini BEST ABSTRACTS I - ORAL PRESENTATIONS Chairmen: R. Hajek, T. Plesner

5 SATURDAY, APRIL 21, MEET THE EXPERTS 6 Simultaneous Sessions Start of therapy in RRMM - P. Moreau, A. Waage Risk adapted therapy in NDMM elderly - M.T. Petrucci, S. Zweegman Special conditions - M. Offidani, L. Rosiñol Imaging: when and in which patients - J. Hillengas, R. Zambello Nurse: management of multiple myeloma patients from a nurse s perspective - A. Bernardini, P. Bosman Biology of multiple myeloma - R. Hajek, M. Kaiser TREATMENT STRATEGY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: NOVEL THERAPIES, WHEN AND IN WHICH PATIENTS? Chairmen: C. Driessen, S. Lonial When to use novel proteasome inhibitors and immunomodulatory drugs - F. Gay When to use other classes of drugs: HDACs, nuclear pore inhibitors, proteomics - E.M. Ocio When to use monoclonal antibodies - N. van de Donk When do we choose checkpoint inhibitors - P. Rodriguez Which will be the best place for bispecific antibodies and novel cellular therapies - H. Einsele BEST ABSTRACTS II - ORAL PRESENTATIONS Chairmen: H. Goldschmidt, E. Terpos RECOMMENDATIONS AND CHALLENGES: HOW TO MAKE SENSE OF THE MANY TREATMENT OPTIONS AVAILABLE AT RELAPSE Chairmen: M.A Dimopoulos, G. Jackson DEBATE: START OF THERAPY Biological or clinical relapse? Biological - M. Boccadoro Biological or clinical relapse? Clinical - S. Lonial How to use newest combinations: is there an optimal sequencing? - X. Leleu Cost/efficacy considerations - J.L. Harousseau RRMM? - P. Moreau SIDE EFFECTS MANAGEMENT Chairmen: H. Ludwig, A. Waage How I treat bone disease - E. Terpos How I treat drug toxicity - S. Bringhen How I treat infections - M. Delforge How I treat renal failure - H. Ludwig CONCLUSIONS AND FINAL GREETINGS LIGHT LUNCH